Simone Poli1, Lia Bally2, Roland Wiest3, and Roland Kreis1
1Department of Radiology and Biomedical Research, University of Bern, Bern, Switzerland, 2Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital and University of Bern, Bern, CH, Bern, Switzerland, 3Institute of Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital and University of Bern, Bern, CH, Bern, Switzerland
1Department of Radiology and Biomedical Research, University of Bern, Bern, Switzerland, 2Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital and University of Bern, Bern, CH, Bern, Switzerland, 3Institute of Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital and University of Bern, Bern, CH, Bern, Switzerland
To evaluate
feasibility of indirect 1H MRS detection of metabolic changes after
intake of deuterated glucose, brain spectra were simulated and minimal fitting
uncertainties determined. We expect labeling of glutamate, lactate and
glutamine to be observable, for large VOIs, but also in MRSI
Figure 1. a) Simulated basis spectra with expected in vivo
lineshape at equal concentrations for glutamate, glutamine, lactate, glucose, and
their mono- and double- deuterated counterparts. b) Synthetic normal
brain spectrum with main metabolite peaks labeled vs. the expected brain spectrum
after supplementation of deuterated glucose with effect size taken from Ref. 3 and
c) difference between the two, amplified
by a factor of 15 for better visualization.
Figure 2. Comparison
of simulated and measured phantom spectra of [6,6’-2H2]-Glc and [6,6’-1H2]-Glc
at high resolution to verify the appropriateness of the simulations and thus
the applicability of the precision estimation based on CRB calculations in
synthetic spectra with in vivo conditions.
